Two “Compassionate Use” Expanded Access Programs (EAPs) provided access to treatment with CNM-Au8 to more than 250 people living with amyotrophic lateral sclerosis (ALS). A significant survival ...
First patient, first visit is planned for early June 2024 Enrollment has been expanded by 80% to a maximum of 180 participants ‘Real-world’ drug efficacy data will be collected by monitoring potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results